|Mr. William B. Stilley III, M.B.A., MBA||Chairman, Pres & CEO||614.1k||N/A||1968|
|Dr. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych||Founder & Chief Medical Officer||375k||N/A||1960|
|Mr. Joseph M. Truluck M.B.A., MBA||CFO, COO, Treasurer & Sec.||225.03k||N/A||1978|
|Dr. Jack W. Reich||Head of Regulatory||17.01k||N/A||1949|
|Mr. Alex Lugovoy||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Mark H. Peikin||Chief Strategy Officer||N/A||N/A||N/A|
|Mr. Lawrence Goldman||Controller||N/A||N/A||1956|
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.